Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in Japan
Treatment for lung cancer continues to rapidly evolve. Here, we describe trends in the initial treatment of adults with newly diagnosed primary non-small-cell lung cancer in Japan. This retrospective cohort study used data from JMDC Inc. Claims Database from 2015 to 2023. Adults with lung cancer, co...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/1/32 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588713206480896 |
|---|---|
| author | Qingqing Hu Kuan-Chih Huang Ko Nakajo Yongjing Zhang Hong Qiu |
| author_facet | Qingqing Hu Kuan-Chih Huang Ko Nakajo Yongjing Zhang Hong Qiu |
| author_sort | Qingqing Hu |
| collection | DOAJ |
| description | Treatment for lung cancer continues to rapidly evolve. Here, we describe trends in the initial treatment of adults with newly diagnosed primary non-small-cell lung cancer in Japan. This retrospective cohort study used data from JMDC Inc. Claims Database from 2015 to 2023. Adults with lung cancer, confirmed using a combination of diagnosis, treatment, or procedure codes, were enrolled. A total of 9373 patients were included, with a mean age of approximately 59 years. The median time from diagnosis to treatment initiation ranged from 38 days in patients treated surgically to 25 days in patients with distant metastases. The observed trends were a decrease in the percentage of newly diagnosed patients with distant metastases, a decline in chemotherapy use in patients with early-stage disease, and in advanced disease, a more than doubling in the use of targeted therapy, including checkpoint inhibitors, while radiotherapy and chemotherapy tended to decrease. The observed changes in treatment were driven mainly by the increased use of targeted therapies including checkpoint inhibitors and are aligned with current treatment guidelines in Japan. The observation of fewer patients with distant metastases over time possibly indicates earlier detection. Additional research is needed to understand if new therapies are being extended to older and frail patients with lung cancer in Japan. |
| format | Article |
| id | doaj-art-93e7d24f3476428fbac9053c5132e0ab |
| institution | Kabale University |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-93e7d24f3476428fbac9053c5132e0ab2025-01-24T13:28:25ZengMDPI AGCurrent Oncology1198-00521718-77292025-01-013213210.3390/curroncol32010032Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in JapanQingqing Hu0Kuan-Chih Huang1Ko Nakajo2Yongjing Zhang3Hong Qiu4Global Epidemiology, Office of the Chief Medical Officer, Janssen Research & Development, LLC, Shanghai 200231, ChinaGlobal Epidemiology, Office of the Chief Medical Officer, Janssen Research & Development, LLC, Taipei 104, TaiwanGlobal Epidemiology, Office of the Chief Medical Officer, Janssen Research & Development, LLC, Tokyo 101-0065, JapanGlobal Epidemiology, Office of the Chief Medical Officer, Janssen Research & Development, LLC, Shanghai 200231, ChinaGlobal Epidemiology, Office of the Chief Medical Officer, Janssen Research & Development, LLC, Titusville, NJ 08560, USATreatment for lung cancer continues to rapidly evolve. Here, we describe trends in the initial treatment of adults with newly diagnosed primary non-small-cell lung cancer in Japan. This retrospective cohort study used data from JMDC Inc. Claims Database from 2015 to 2023. Adults with lung cancer, confirmed using a combination of diagnosis, treatment, or procedure codes, were enrolled. A total of 9373 patients were included, with a mean age of approximately 59 years. The median time from diagnosis to treatment initiation ranged from 38 days in patients treated surgically to 25 days in patients with distant metastases. The observed trends were a decrease in the percentage of newly diagnosed patients with distant metastases, a decline in chemotherapy use in patients with early-stage disease, and in advanced disease, a more than doubling in the use of targeted therapy, including checkpoint inhibitors, while radiotherapy and chemotherapy tended to decrease. The observed changes in treatment were driven mainly by the increased use of targeted therapies including checkpoint inhibitors and are aligned with current treatment guidelines in Japan. The observation of fewer patients with distant metastases over time possibly indicates earlier detection. Additional research is needed to understand if new therapies are being extended to older and frail patients with lung cancer in Japan.https://www.mdpi.com/1718-7729/32/1/32lung cancertargeted therapycheckpoint inhibitorchemotherapyJapan |
| spellingShingle | Qingqing Hu Kuan-Chih Huang Ko Nakajo Yongjing Zhang Hong Qiu Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in Japan Current Oncology lung cancer targeted therapy checkpoint inhibitor chemotherapy Japan |
| title | Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in Japan |
| title_full | Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in Japan |
| title_fullStr | Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in Japan |
| title_full_unstemmed | Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in Japan |
| title_short | Initial Treatment Modalities in Patients with Newly Diagnosed Primary Lung Cancer in Japan |
| title_sort | initial treatment modalities in patients with newly diagnosed primary lung cancer in japan |
| topic | lung cancer targeted therapy checkpoint inhibitor chemotherapy Japan |
| url | https://www.mdpi.com/1718-7729/32/1/32 |
| work_keys_str_mv | AT qingqinghu initialtreatmentmodalitiesinpatientswithnewlydiagnosedprimarylungcancerinjapan AT kuanchihhuang initialtreatmentmodalitiesinpatientswithnewlydiagnosedprimarylungcancerinjapan AT konakajo initialtreatmentmodalitiesinpatientswithnewlydiagnosedprimarylungcancerinjapan AT yongjingzhang initialtreatmentmodalitiesinpatientswithnewlydiagnosedprimarylungcancerinjapan AT hongqiu initialtreatmentmodalitiesinpatientswithnewlydiagnosedprimarylungcancerinjapan |